Sparing androgen-deprivation therapy upon treatment with abiraterone in patients with chemotherapy-naive castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)

Autor:	J. Telle, R. Zilmann, M. Scheffler, J. Klier, Henrik Suttmann, J. Gleißner, Susan Feyerabend, A. Hübner, M. Jäschke, C.H. Ohlmann, Martin Janssen, C. Rüssel, J. Dahm, E. Hellmis, J. Marin
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Urology Castration resistant medicine.disease Androgen deprivation therapy Abiraterone chemistry.chemical_compound Prostate cancer chemistry Internal medicine Medicine In patient business Chemotherapy naive
Zdroj:	European Urology Supplements. 18:e1390-e1391
ISSN:	1569-9056
DOI:	10.1016/s1569-9056(19)31006-1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::35c198958f45b1efe567a9e16757384d https://doi.org/10.1016/s1569-9056(19)31006-1 Zobrazit plný text záznamu Full Text from ScienceDirect